What firm manufactured the NeuroMax Cartridge and what corrective actions did they announce in the FDA recall letter?
Executive summary
The FDA’s public database lists a Class 2 recall for the “NeuroMax Cartridge,” and that recall record is the primary public source for who manufactured the product and what corrective actions were announced [1]. The reporting supplied for this query does not include the text of the recall letter itself, so the manufacturer name and the precise corrective-action language cannot be quoted here from the provided sources; the FDA entry is the place to find those definitive details [1] [2].
1. The record that matters: where the authoritative details live
The official starting point for authoritative information on the NeuroMax Cartridge recall is the FDA’s recall database entry titled “Class 2 Device Recall NeuroMax Cartridge,” which is the record that contains the recall letter and accompanying manufacturer details [1]. The FDA’s recall pages routinely host the recall communication, reason for recall, the firm’s legal name, the scope of distribution, and the corrective actions the firm committed to — and the NeuroMax Cartridge entry is the database record to consult for those elements [1] [2].
2. What the available reporting actually shows (and what it does not)
The supplied search results include the NeuroMax Cartridge recall record’s listing but do not include the recall letter text or a scraped excerpt naming the firm or listing the corrective actions, so the specific firm that manufactured the NeuroMax Cartridge and the exact corrective measures announced are not present in the materials provided for this query [1]. The FDA page header and metadata confirm the existence of a Class 2 recall entry for NeuroMax Cartridge, but the recall letter’s operative language — who, what, where, and how the firm will correct or retrieve product — is not among the supplied snippets [1].
3. How FDA recall entries normally convey corrective actions — why the page matters
FDA recall pages for medical devices typically record the manufacturer’s description of corrective actions — for example product quarantine, notification to customers, return or destruction instructions, and revised labeling or process changes — and the agency’s classification and rationale for oversight [2]. That procedural context explains why the NeuroMax Cartridge entry on the FDA site should contain the manufacturer name and the firm’s announced corrective actions, and why consulting that specific recall entry is necessary to obtain verbatim corrective-action commitments and timelines [1] [2].
4. Alternative sources and cross-checking the record
Other FDA recall listings and third-party aggregators sometimes republish recall summaries, and larger or high-impact recalls are often accompanied by press releases from the manufacturer or distributors and reporting by medical trade press [3] [4]. Because the supplied dataset includes only the FDA index entry for NeuroMax Cartridge and not the recall letter text or third-party coverage, confirming the firm name and the exact corrective actions will require opening the FDA recall page linked in the record or finding a contemporaneous manufacturer notice that repeats the same language [1] [4].
5. Judgment and transparency about limits of available evidence
Given the constraints of the supplied reporting, one cannot responsibly state the manufacturer’s name or quote the corrective actions from the FDA recall letter without consulting the recall page itself; the recall record exists and is the authoritative source, but the content needed to directly answer the user’s two-part question was not included in the materials provided for analysis [1] [2]. The correct next step is to open the FDA’s “Class 2 Device Recall NeuroMax Cartridge” record to read the firm’s legal name and the precise corrective-action commitments recorded in the recall letter [1].